BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30950242)

  • 1. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
    Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
    Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
    BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy.
    Arnot SP; Han G; Fortino J; Han D; Fowler G; Vetto JT
    Am J Surg; 2021 Jun; 221(6):1195-1199. PubMed ID: 33773750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
    Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
    J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma.
    Kangas-Dick AW; Greenbaum A; Gall V; Groisberg R; Mehnert J; Chen C; Moore DF; Berger AC; Koshenkov V
    Ann Surg Oncol; 2021 Aug; 28(8):4582-4589. PubMed ID: 33486642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
    Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Expression Profiling Prognostication of Posterior Uveal Melanoma: Does Size Matter?
    Binkley EM; Bena JF; Davanzo JM; Hinz C; Boldt HC; Singh AD
    Ophthalmol Retina; 2020 Jun; 4(6):620-629. PubMed ID: 32081600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma.
    Jarell A; Skenderis B; Dillon LD; Dillon K; Martin B; Quick AP; Siegel JJ; Rackley BB; Cook RW
    Future Oncol; 2021 Dec; 17(36):5023-5031. PubMed ID: 34587770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma sentinel node biopsy and prediction models for relapse and overall survival.
    Mitra A; Conway C; Walker C; Cook M; Powell B; Lobo S; Chan M; Kissin M; Layer G; Smallwood J; Ottensmeier C; Stanley P; Peach H; Chong H; Elliott F; Iles MM; Nsengimana J; Barrett JH; Bishop DT; Newton-Bishop JA
    Br J Cancer; 2010 Oct; 103(8):1229-36. PubMed ID: 20859289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.
    Amaral TMS; Hoffmann MC; Sinnberg T; Niessner H; Sülberg H; Eigentler TK; Garbe C
    Eur J Cancer; 2020 Jan; 125():38-45. PubMed ID: 31838403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study.
    Oude Ophuis CM; Verhoef C; Rutkowski P; Powell BW; van der Hage JA; van Leeuwen PA; Voit CA; Testori A; Robert C; Hoekstra HJ; Grünhagen DJ; Eggermont AM; van Akkooi AC
    Eur J Surg Oncol; 2016 Dec; 42(12):1906-1913. PubMed ID: 27266406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
    Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
    J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incomplete sentinel node biopsy is not clearly related to survival or regional recurrence in cutaneous melanoma patients.
    Lee NC; Spillane AJ; Pang TC; Haydu LE; Uren RF
    Ann Surg Oncol; 2012 Jan; 19(1):280-6. PubMed ID: 21833669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.
    Gerami P; Cook RW; Russell MC; Wilkinson J; Amaria RN; Gonzalez R; Lyle S; Jackson GL; Greisinger AJ; Johnson CE; Oelschlager KM; Stone JF; Maetzold DJ; Ferris LK; Wayne JD; Cooper C; Obregon R; Delman KA; Lawson D
    J Am Acad Dermatol; 2015 May; 72(5):780-5.e3. PubMed ID: 25748297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival.
    Oude Ophuis CM; van Akkooi AC; Rutkowski P; Voit CA; Stepniak J; Erler NS; Eggermont AM; Wouters MW; Grünhagen DJ; Verhoef CK
    Eur J Cancer; 2016 Nov; 67():164-173. PubMed ID: 27669503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
    Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
    J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
    Wisco OJ; Marson JW; Litchman GH; Brownstone N; Covington KR; Martin BJ; Quick AP; Siegel JJ; Caruso HG; Cook RW; Winkelmann RR; Rigel DS
    Melanoma Res; 2022 Apr; 32(2):98-102. PubMed ID: 35254332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.
    Kött J; Zimmermann N; Zell T; Rünger A; Heidrich I; Geidel G; Smit DJ; Hansen I; Abeck F; Schadendorf D; Eggermont A; Puig S; Hauschild A; Gebhardt C
    Eur J Cancer; 2024 May; 202():113989. PubMed ID: 38518535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma.
    Doubrovsky A; De Wilt JH; Scolyer RA; McCarthy WH; Thompson JF
    Ann Surg Oncol; 2004 Sep; 11(9):829-36. PubMed ID: 15313732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck.
    Gastman BR; Zager JS; Messina JL; Cook RW; Covington KR; Middlebrook B; Gerami P; Wayne JD; Leachman S; Vetto JT
    Head Neck; 2019 Apr; 41(4):871-879. PubMed ID: 30694001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.